Helix BioPharma (TSE:HBP) Stock Crosses Above 50 Day Moving Average of $0.21

Helix BioPharma Corp. (TSE:HBPGet Rating)’s share price passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$0.21 and traded as high as C$0.22. Helix BioPharma shares last traded at C$0.21, with a volume of 23,219 shares trading hands.

Helix BioPharma Trading Down 10.9 %

The company has a 50 day moving average price of C$0.21 and a 200 day moving average price of C$0.21. The firm has a market cap of C$41.00 million and a price-to-earnings ratio of -3.66. The company has a debt-to-equity ratio of 773.67, a quick ratio of 1.04 and a current ratio of 1.08.

Helix BioPharma (TSE:HBPGet Rating) last posted its earnings results on Wednesday, December 14th. The biopharmaceutical company reported C($0.01) earnings per share (EPS) for the quarter. On average, research analysts expect that Helix BioPharma Corp. will post -0.11 earnings per share for the current year.

Helix BioPharma Company Profile

(Get Rating)

Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.

Recommended Stories

Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.